<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00277160</url>
  </required_header>
  <id_info>
    <org_study_id>20020122</org_study_id>
    <nct_id>NCT00277160</nct_id>
  </id_info>
  <brief_title>A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (&gt;/= 65 Years Old) With Cancer</brief_title>
  <official_title>A Randomized, Open Label, Multicenter Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis as an Adjunct to Chemotherapy in Elderly Subjects (&gt;/= 65 Years Old) With Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess pegfilgrastim starting with the first cycle versus
      secondary prophylaxis on neutropenic events (including neutropenia +/- fever, dose delays,
      dose reductions, and hospitalizations) in older patients receiving chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of febrile neutropenia, defined by ANC &lt; 1.0 x 10^9/L and temperature ≥ 38o C on the same day</measure>
    <time_frame>End of the last cycle of chemotherapy or the date of early termination from the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade 3 and 4 neutropenia</measure>
    <time_frame>End of the last cycle of chemotherapy or the date of early termination from the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose delays or dose reductions</measure>
    <time_frame>End of the last cycle of chemotherapy or the date of early termination from the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of febrile neutropenia with a more strict definition (ANC &lt; 0.5 x 10^9/L and temperature ≥ 38o C), on the same day</measure>
    <time_frame>End of the last cycle of chemotherapy or the date of early termination from the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">852</enrollment>
  <condition>Neutropenia</condition>
  <condition>Breast Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment Group 1 (Primary Prophylaxis)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neulasta 6mg single administration per cycle of chemotherapy starting with cycle 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group 2 (Secondary Prophylaxis)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Per Investigator's discretion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neulasta (pegfilgrastim)</intervention_name>
    <description>Commercial pegfilgrastim 6mg single subcutaneous fixed-dose</description>
    <arm_group_label>Treatment Group 1 (Primary Prophylaxis)</arm_group_label>
    <arm_group_label>Treatment Group 2 (Secondary Prophylaxis)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;/= 65 years old

          -  documented diagnosis of lung, breast, or ovarian cancer, or NHL

          -  scheduled to receive one of 15 standard chemotherapy regimens

          -  chemotherapy naive OR have received adjuvant therapy AND/OR have no more than one
             regimen of chemotherapy for metastatic disease

          -  life expectancy of at least 3 months

          -  ECOG performance status &lt;/=2

          -  adequate renal and hematologic function

          -  informed consent for participation in the study prior to any study specific procedures

        Exclusion Criteria:

          -  known hypersensitivity to any of the products to be administered during dosing

          -  primary prophylactic antibiotics in all cycles

          -  prior radiation therapy within 2 weeks of randomization into this study or plan for
             radiation therapy during study participation, except for spot radiation for bony
             metastases

          -  prior bone marrow or stem cell transplant or plan to receive any transplant therapy
             during study participation

          -  clinically symptomatic brain metastases

          -  Folstein mini-mental state exam score &lt;18

          -  Any premalignant myeloid condition or any malignancy with myeloid characteristics

          -  History of prior malignancy within the last 5 years other than subject's original
             cancer diagnosis listed in inclusion criteria with the exception of curatively treated
             basal cell carcinoma, squamous cell carcinoma, in situ cervical carcinoma or
             surgically cured malignancies

          -  unstable/uncontrolled cardiac conditions or hypertension

          -  active infection

          -  subject is currently enrolled or has not yet completed at least 30 days since ending
             other investigational device or drug trial or is receiving other investigational
             agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <results_reference>
    <citation>Balducci L, Al-Halawani H, Charu V, Tam J, Shahin S, Dreiling L, Ershler WB. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist. 2007 Dec;12(12):1416-24. doi: 10.1634/theoncologist.12-12-1416.</citation>
    <PMID>18165618</PMID>
  </results_reference>
  <results_reference>
    <citation>Flores IQ, Ershler W. Managing neutropenia in older patients with cancer receiving chemotherapy in a community setting. Clin J Oncol Nurs. 2010 Feb;14(1):81-6. doi: 10.1188/10.CJON.81-86.</citation>
    <PMID>20118030</PMID>
  </results_reference>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2006</study_first_submitted>
  <study_first_submitted_qc>January 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2006</study_first_posted>
  <last_update_submitted>October 7, 2010</last_update_submitted>
  <last_update_submitted_qc>October 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

